Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. It's portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Windtree Therapeutics Inc market cap is $13,496.00.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Windtree Therapeutics Inc 52 week high is $0.065 as of November 18, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Windtree Therapeutics Inc 52 week low is $0.0001 as of November 18, 2026.
Windtree Therapeutics Inc stock price today is $0.0003.
Windtree Therapeutics Inc stock price yesterday was $0.0002.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Windtree Therapeutics Inc P/B ratio is -0.0009.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Windtree Therapeutics Inc 50-day moving average is $0.0007.